Table 2. Morphological and biochemical characteristics of subjects with lower and higher ‘cumulative blood platelet reactivity’.
| Parameter |
Individuals with lower ‘cumulative blood platelet reactivity’ (n= 77) |
Individuals with higher ‘cumulative blood platelet reactivity’ (n= 78) |
| age (years) | 63 (62 - 65) | 62 (61 - 64) |
| men [%] | 64.9 | 29.5 |
| WBC (103/mm3) | 5.6 (4.8 – 6.4) | 5.8 (5.2 – 7.0) U* |
| RBC (103/mm3) | 4.5 ± 0.4 | 4.5 ± 0.4 |
| HGB (g/dl) | 14.0 ± 1.1 | 13.8 ± 1.0 |
| HCT (%) | 40.1 ± 2.9 | 39.3 ± 2.6 U* |
| PLT (103/mm3) | 196.1 ± 36.9 | 228.7 ± 47.8 T††† |
| MPV (µm3) | 11.1 ± 0.9 | 11.5 ± 0.1 T* |
| PCT (%) | 0.22 ± 0.04 | 0.26 ± 0.05 T††† |
| P-LCR (%) | 33.9 ± 7.6 | 37.2 ± 7.8 T* |
| PDW | 12.9 (12.0 – 15.3) | 13.8 (12.6 – 15.9) |
| Lym (103/mm3) | 1.72 (1.46 – 2.23) | 2.02 (1.57 – 2.43) |
| Mono (103/mm3) | 0.52 (0.44 – 0.62) | 0.53 (0.42 – 0.65) |
| Neu (103/mm3) | 3.10 (2.47 – 3.68) | 3.14 (2.61 – 3.95) U* |
| Eo (103/mm3) | 0.14 (0.10 – 0.24) | 0.15 (0.10 – 0.22) |
| Baso (103/mm3) | 0.03 (0.02 – 0.03) | 0.02 (0.02 – 0.03) |
| total cholesterol (mg/dl) | 206.0 (171.8 – 244.2) | 211.5 (178.9 – 241.7) |
| triglycerides (mg/dl) | 113.9 (77.6 – 162.0) | 108.6 (82.5 – 161.9) |
| HDL cholesterol (mg/dl) | 47.3 (41.4 – 54.0) | 52.3 (42.6 – 63.6) |
| LDL cholesterol (mg/dl) | 130.3 ± 38.8 | 136.8 ± 35.1 |
| glucose (mg/dl) | 99.2 (90.1 – 107.8) | 97.2 (90.3 – 105.6) |
| uric acid (mg/dl) | 5.3 ± 1.3 | 4.8 ± 1.1 T†† |
| homocysteine (µmol/l) | 14.3 (12.4 – 19.2) | 15.2 (13.2 – 17.0) |
| testosterone (ng/ml) | 4.5 (3.1 – 4.6) | 2.9 (2.9 – 4.4) U††† |
| dihydrotestosterone (ng/ml) | 0.6 (0.3 – 0.7) | 0.3 (0.3 – 0.6) U††† |
| oestradiol (ng/ml) | 0.04 (0.03 – 0.06) | 0.04 (0.03 - 0.05) |
Variables, adjusted for age and sex, presented as means ± SD, medians with interquartile ranges or percent fractions of whole groups of investigated patients. The individuals with lower or higher ‘cumulative blood platelet reactivity’ were identified according to the dichotomised values of the van der Waerden normal scores of Amax cumulated through the agonists used (AA, collagen, ADP), referred to as ‘cumulative blood platelet reactivity’ (see details in Materials and methods and Results).
Comparisons between the groups were performed on the Box-Cox-transformed adjusted values with the use of covariance analysis (ANCOVA): *P≤ 0.05; #P< 0.01; †P< 0.005; ††P< 0.001; †††P<< 0.0001.
Abbreviations used: Baso, number of basophils; BMI, body mass index; Eo, number of eosinophils; HCT, haematocrit; HDL, high density lipoproteins; HGB, concentration of haemoglobin; LDL, low density lipoproteins; LYM, number of lymphocytes; Mono, number of monocytes; MPV, mean platelet volume; Neu, number of neutrophils; PCT, plateletcrit; PDW, platelet distribution width; P-LCR, platelet-large cells ratio; PLT, platelet count; RBC, red blood cell count; WBC, white blood cell count.